Cellebrite DI (NASDAQ:CLBT) Shares Up 9.8% – Here’s Why

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) shot up 9.8% on Friday . The company traded as high as $14.43 and last traded at $14.4990. 1,505,539 shares traded hands during trading, a decline of 21% from the average session volume of 1,917,233 shares. The stock had previously closed at $13.20.

Analyst Ratings Changes

A number of research firms have commented on CLBT. Needham & Company LLC reduced their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. DA Davidson began coverage on Cellebrite DI in a research report on Wednesday. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Cellebrite DI Stock Up 9.8%

The stock has a market capitalization of $3.62 billion, a PE ratio of 51.77, a P/E/G ratio of 1.52 and a beta of 1.15. The firm has a 50 day moving average price of $13.26 and a 200 day moving average price of $15.30.

Insider Activity at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive directly owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 13,269 shares of company stock valued at $169,592 over the last three months. Corporate insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently bought and sold shares of the company. Voss Capital LP grew its holdings in Cellebrite DI by 18.9% during the fourth quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock valued at $145,142,000 after purchasing an additional 1,277,300 shares during the period. Pertento Partners LLP grew its holdings in Cellebrite DI by 28.2% during the fourth quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after purchasing an additional 1,311,109 shares during the period. Invesco Ltd. grew its holdings in Cellebrite DI by 0.8% during the fourth quarter. Invesco Ltd. now owns 5,603,237 shares of the company’s stock valued at $101,026,000 after purchasing an additional 43,041 shares during the period. Granahan Investment Management LLC grew its holdings in Cellebrite DI by 16.3% during the fourth quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock valued at $55,118,000 after purchasing an additional 427,719 shares during the period. Finally, Cooper Creek Partners Management LLC bought a new position in Cellebrite DI during the third quarter valued at $55,999,000. 45.88% of the stock is owned by institutional investors.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.